INDEX TO VOLUME 173

Author Index

Aaby, P., 245
Aaldering, L., 1164
Abbud, R. A., 1046
Abrams, E. J., 68
Abrams, J., 1521
Abrams, J. S., 769
Acheson, D. W. K., 1164
Adler, B., 971
Adler, H., 971
Aguado, J. M., 1072
Aguero, S. M., 656
Ahlm, C., 38
Ahmed, F., 83
Ait-Cheik, L., 565
Akiyoshi, H., 1485
Akridge, R. E., 559
Alcabes, P., 1252
Alemu, W., 1470
Alexander, J. P., Jr., 1470
Ali, M., 226
Allen, S., 765
Almeida, A. C. M., 1077
Almquist, J. R., 180
Alonso, J.-M., 1123
Alt, S., 1267
Alter, M. J., 822
Ambrosino, D. M., 256
Anderson, B. D., 1485
Anderson, E. L., 1014, 1313, 1467
Anderson, L. J., 1470
Anderson, W. R., 1194
Ando, T., 787
Andreoni, M., 1379
Andriole, V. T., 517
Andrus, L., 808
Angiolella, L., 684
Angus, B., 691
ANRS 005-ACTG 154 Group Members, 91
Apicella, M. A., 636
Araneo, B. A., 536
Araujo, M. I., 269
Arden, N., 453
Arduino, M. J., 656
Arichi, T., 24
Ariyoshi, K., 245
Arlievsky, N., 574
Armstrong, L. R., 1297
Arno, J. N., 394
Asanuma, H., 503
Ascher, M. S., 781
Assil, K. K., 18
Atoui, N., 565
Aubertin, J., 91
Aukrust, P., 259
Ausiello, C. M., 1030
Auwaerter, P. G., 237
Awadzi, K., 1277
Baba, E., 1115
Bacellar, O., 1515
Bachman, S. E., 550
Bachur, R., 870
Badaró, R., 758
Badley, A. D., 446
Bagasra, O., 550
Bairati, I., 794
Baker, C. J., 142
Bakken, J. S., 1027
Bakshi, S., 68
Balfour-Lynn, I., 1049
Bamji, M., 68
Banatvala, N., 480
Barbosa, P., 476
Barbour, A. G., 403, 1184
Barker, S., 1092
Barnish, G., 765
Barral-Netto, M., 1515
Barrett, L. K., 491
Barrett, T. J., 480
Barron, P., 1320
Bartemes, K. R., 1277
Bartlett, J. A., 849
Baseler, M., 840
Bass, R., 735
Bates, I., 691
Bates, J. H., 934
Bauer, S. P., 1297
Baughman, W., 365
Baumberger, C., 1388
Bautista, R. M., 1062
Beach, M., 822
Bean, N. H., 480
Beatty, D., 1320
Bechtel, C., 840
Beck, J. M., 432
Becker, I., 699
Beckett, L., 1336
Behling, C. A., 942
Belasco, D., 187
Belay, E. D., 787
Belay, S. M., 340
Bell, A., 1009
Bellini, W. J., 32, 1470
Belshe, R. B., 330, 340, 1467
Belshe, R. B. for the National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Program, 1313
Beninga, J., 1051
Bennett, R. W., 1263
Benowitz, N. B., 273
Benson, D., 758
Benton, K., 777
Berardi, C. J., 1327
Beretta, A., 472
Bergamini, A., 1367
Berger, M., 514
Bergeron-Lynn, G., 18
Berkower, I., 863
Berline, J., 710
Berman, P. W., 52
Bernard, J., 1485
Bernard, P., 794
Bernstein, D. I., 1, 800
Berry, N., 245
Berthier, A.-M., 565
Berzofsky, J. A., 24, 472, 1085
Besen, G., 18
Bessen, D. E., 896
Betts, R. F., 1467
Beyene, H., 1470
Bhan, M. K., 1019
Bhatnagar, P. K., 203
Bhattacharjee, A. K., 1157
Bibb, W. F., 480
Bigoni, B., 542
Bilello, J. A., 464, 849, 1524
Bilska, M., 60
Binder, P., 1123
Blake, M. S., 636
Bland, L. A., 656
Blattner, W. A., 718
Bleijenberg, G., 460
Bloigu, A., 387
Blum, J., 1273
Blumberg, H. M., 365
Bobrin, B. D., 656
Boden, G., 550
Bodey, G. P., 418, 495
Boelaert, J. R., 1045
Boelens, H. A. M., 914
Boiocchi, M., 542
Boivin, G., 523, 1304
Bollen, A., 1202
Bonomo, R. A., 151
Boriga, D. A., 1284
Borkowsky, W., 574, 1097
Borsboom, A. N. J., 1148
Borucki, M., 1336
Bost, K. L., 627
Boswell, R. N., 877
Bouchard, C., 794
Bourgeault, A., 1034
Bourne, N., 1, 800
Bowden, R. A., 1208
Boyer, P., 1001
Boyle, M. D. P., 104, 888
Brady, M. T., 1097
Brandt, C. M., 909
Brandtzaeg, P., 647
Brar, D. W., 739
Bravo, F. J., 1
Bravo, R., 509
Breiman, R. F., 374
Brett-Smith, H., 1252
Brihmer, C., 1394
Briles, D. E., 380, 777
Brisson, J., 794
Brochu, S., 1034
Bröcker, E.-B., 699
Brodskyn, C., 1515
Brookmeyer, R., 579
Brotman, B., 808
Brouwers, P., 1097
Brown, A. E., 1523
Brown, B. W., 265
Brown, C., 718
Brown, D., 32
Brown, H., 727
Brown, J. J., 746, 920
Brown, T., 781
Brownlee, A. G., 754
Brummer, E., 677, 750
Brunham, R. C., 950, 1437
Bryan, R. T., 1297, 781
Bryant, A. E., 619
Bryson, Y. J., 1001, 1097
Buchbinder, S., 476
Buffington, J., 453
Bui, P. T., 829
Bull, T. E., 863
Buma, A. P. C. C. H., 1506
Buonnano, E., 1367
Burke, D. S., 877
Burke, D. S. for the National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group, 340
Burns, J. M., 758
Burton, A., 237
Bussiere, J., 52
Buttery, L. K., 1399
Buurman, W. A., 252
Bwayo, J. J., 950, 1437
Caldwell, B., 870
Campagnari, A. A., 394
Campbell, G. L., 1528
Campbell, L. A., 1519
Canfield, D. R., 1327
Canner, J. K., 714
Capozzi, M., 1367
Cappannoli, L., 1367
Cappuccio, A. L., 1519
Carabaña, J., 32
Carballo, E., 509
Carbone, A., 542
Carcelen, R., 279
Carelse, E., 1320
Carias, L. L., 151
Carneiro-Sampaio, M. M. S., 1077

INDEX TO VOLUME 173

Author Index

Aaby, P., 245
Aaldering, L., 1164
Abbud, R. A., 1046
Abrams, E. J., 68
Abrams, J., 1521
Abrams, J. S., 769
Acheson, D. W. K., 1164
Adler, B., 971
Adler, H., 971
Aguado, J. M., 1072
Aguero, S. M., 656
Ahlm, C., 38
Ahmed, F., 83
Ait-Cheik, L., 565
Akiyoshi, H., 1485
Akridge, R. E., 559
Alcabes, P., 1252
Alemu, W., 1470
Alexander, J. P., Jr., 1470
Ali, M., 226
Allen, S., 765
Almeida, A. C. M., 1077
Almquist, J. R., 180
Alonso, J.-M., 1123
Alt, S., 1267
Alter, M. J., 822
Ambrosino, D. M., 256
Anderson, B. D., 1485
Anderson, E. L., 1014, 1313, 1467
Anderson, L. J., 1470
Anderson, W. R., 1194
Ando, T., 787
Andreoni, M., 1379
Andriole, V. T., 517
Andrus, L., 808
Angiolella, L., 684
Angus, B., 691
ANRS 005-ACTG 154 Group Members, 91
Apicella, M. A., 636
Araneo, B. A., 536
Araujo, M. I., 269
Arden, N., 453
Arduino, M. J., 656
Arichi, T., 24
Ariyoshi, K., 245
Arlievsky, N., 574
Armstrong, L. R., 1297
Arno, J. N., 394
Asanuma, H., 503
Ascher, M. S., 781
Assil, K. K., 18
Atoui, N., 565
Aubertin, J., 91
Aukrust, P., 259
Ausiello, C. M., 1030
Auwaerter, P. G., 237
Awadzi, K., 1277
Baba, E., 1115
Bacellar, O., 1515
Bachman, S. E., 550
Bachur, R., 870
Badaró, R., 758
Badley, A. D., 446
Bagasra, O., 550
Bairati, I., 794
Baker, C. J., 142
Bakken, J. S., 1027
Bakshi, S., 68
Balfour-Lynn, I., 1049
Bamji, M., 68
Banatvala, N., 480
Barbosa, P., 476
Barbour, A. G., 403, 1184
Barker, S., 1092
Barnish, G., 765
Barral-Netto, M., 1515
Barrett, L. K., 491
Barrett, T. J., 480
Barron, P., 1320
Bartemes, K. R., 1277
Bartlett, J. A., 849
Baseler, M., 840
Bass, R., 735
Bates, I., 691
Bates, J. H., 934
Bauer, S. P., 1297
Baughman, W., 365
Baumberger, C., 1388
Bautista, R. M., 1062
Beach, M., 822
Bean, N. H., 480
Beatty, D., 1320
Bechtel, C., 840
Beck, J. M., 432
Becker, I., 699
Beckett, L., 1336
Behling, C. A., 942
Belasco, D., 187
Belay, E. D., 787
Belay, S. M., 340
Bell, A., 1009
Bellini, W. J., 32, 1470
Belshe, R. B., 330, 340, 1467
Belshe, R. B. for the National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Program, 1313
Beninga, J., 1051
Bennett, R. W., 1263
Benowitz, N. B., 273
Benson, D., 758
Benton, K., 777
Berardi, C. J., 1327
Beretta, A., 472
Bergamini, A., 1367
Berger, M., 514
Bergeron-Lynn, G., 18
Berkower, I., 863
Berline, J., 710
Berman, P. W., 52
Bernard, J., 1485
Bernard, P., 794
Bernstein, D. I., 1, 800
Berry, N., 245
Berthier, A.-M., 565
Berzofsky, J. A., 24, 472, 1085
Besen, G., 18
Bessen, D. E., 896
Betts, R. F., 1467
Beyene, H., 1470
Bhan, M. K., 1019
Bhatnagar, P. K., 203
Bhattacharjee, A. K., 1157
Bibb, W. F., 480
Bigoni, B., 542
Bilello, J. A., 464, 849, 1524
Bilska, M., 60
Binder, P., 1123
Blake, M. S., 636
Bland, L. A., 656
Blattner, W. A., 718
Bleijenberg, G., 460
Bloigu, A., 387
Blum, J., 1273
Blumberg, H. M., 365
Bobrin, B. D., 656
Boden, G., 550
Bodey, G. P., 418, 495
Boelaert, J. R., 1045
Boelens, H. A. M., 914
Boiocchi, M., 542
Boivin, G., 523, 1304
Bollen, A., 1202
Bonomo, R. A., 151
Boriga, D. A., 1284
Borkowsky, W., 574, 1097
Borsboom, A. N. J., 1148
Borucki, M., 1336
Bost, K. L., 627
Boswell, R. N., 877
Bouchard, C., 794
Bourgeault, A., 1034
Bourne, N., 1, 800
Bowden, R. A., 1208
Boyer, P., 1001
Boyle, M. D. P., 104, 888
Brady, M. T., 1097
Brandt, C. M., 909
Brandtzaeg, P., 647
Brar, D. W., 739
Bravo, F. J., 1
Bravo, R., 509
Breiman, R. F., 374
Brett-Smith, H., 1252
Brihmer, C., 1394
Briles, D. E., 380, 777
Brisson, J., 794
Brochu, S., 1034
Bröcker, E.-B., 699
Brodskyn, C., 1515
Brookmeyer, R., 579
Brotman, B., 808
Brouwers, P., 1097
Brown, A. E., 1523
Brown, B. W., 265
Brown, C., 718
Brown, D., 32
Brown, H., 727
Brown, J. J., 746, 920
Brown, T., 781
Brownlee, A. G., 754
Brummer, E., 677, 750
Brunham, R. C., 950, 1437
Bryan, R. T., 1297, 781
Bryant, A. E., 619
Bryson, Y. J., 1001, 1097
Buchbinder, S., 476
Buffington, J., 453
Bui, P. T., 829
Bull, T. E., 863
Buma, A. P. C. C. H., 1506
Buonnano, E., 1367
Burke, D. S., 877
Burke, D. S. for the National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group, 340
Burns, J. M., 758
Burton, A., 237
Bussiere, J., 52
Buttery, L. K., 1399
Buurman, W. A., 252
Bwayo, J. J., 950, 1437
Caldwell, B., 870
Campagnari, A. A., 394
Campbell, G. L., 1528
Campbell, L. A., 1519
Canfield, D. R., 1327
Canner, J. K., 714
Capozzi, M., 1367
Cappannoli, L., 1367
Cappuccio, A. L., 1519
Carabaña, J., 32
Carballo, E., 509
Carbone, A., 542
Carcelen, R., 279
Carelse, E., 1320
Carias, L. L., 151
Carneiro-Sampaio, M. M. S., 1077

Carr, A., 321
Carreño, V., 300
Carrière, D., 565
Carroll, K., 656
Carson, D. A., 822
Carson, L. A., 656
Carter, C. J., 403
Cartter, M. L., 480
Carvalho, E. M., 269, 1515
Casadevall, A., 1222
Casas-Ciria, J., 1519
Cassai, E., 542
Cassone, A., 684
Castro, A., 509
Cater, J., 550
Catrenich, C. E., 1288
Cattaneo, L. A., 1256
Cave, M. D., 934
Cays, M., 1208
Cellini, L., 1288
Celma, M. L., 32
Cepparulo, M., 1367
Chacko, T. M., 1252
Chaisson, R. E., 219, 505, 857
Chambers, G. W., 285
Champe, M., 52
Chan, C. Y., 256
Chang, A., 619
Chang, H. J., 656
Chanock, R. M., 829
Chao, C. C., 1194
Chapman, L. E., 1297
Chappell, C. L., 232
Chariyalertsak, S., 1490
Chaussee, M. S., 901
Cheang, M., 950, 1437
Chen, C.-M., 457
Chen, C.-Y., 394
Chen, M., 24
Chen, S. C. A., 754
Chen, T.-Z., 457
Chêne, G., 91
Cheng, Y.-C., 1252
Cherrington, J. M., 987
Chiba, S., 503
Chiphangwi, J. D., 714
Choi, Y., 1263
Choo, K.-B., 457
Chou, S., 523
Chou, T.-C., 355
Christen, A., 794
Christenson, J. C., 656
Christner, R. B., 104
Chuck, S., 248
Chung, R. C. Y., 1523
Chyou, P.-H., 1474
Clarke, L. M., 77
Clements, J. D., 627
Clements, M. L., 44, 340
Clerici, M., 472, 1085
Cloud, G. A., 499
Cobb, E. K., 52
Coffman, R. L., 1515
Cohen, J., 870, 1399
Cohen, O. J., 849
Cohn, J., 849
Cohn, S., 579
Coleman, R., 273
Colina, K. F., 180
Colmenero, M., 509
Conant, M., 248
Connor, J. D., 18
Connors, M., 829
Coolbaugh, R., 1273
Cooper, D. A., 321, 1092, 1354
Cooper, J. A. D., Jr., 279
Cosma, A., 472
Costa, C. H., 1515
Couch, R., 453
Cox, N., 453
Coyle, B. S., 1260
Cranston, B., 718
Craven, R. B., 1528
Cravioto, A., 1019
Cross, A. S., 1157, 1415, 1422
Cross, J., 440
Crowe, J. E., Jr., 829
Culbreth, R., 279
Cummings, P. K., 957, 1519
Cunha, S., 758
Cunningham, A. L., 7
Cutright, J. L., 425
Daidone, B. J., 77
Dallabetta, G. A., 714
Daly, J. A., 656
Danforth, J. M., 159
Daniel, R. W., 714
Dankert, J., 1171
Darouiche, R., 418
Davey, R. T., Jr., 840
Davey, V., 840
David, J. R., 758
Davidson, F., 727
Davison, D., 52
Daynes, R. A., 536
Deal, C. D., 1422
de Almeida, A. B., 1453
Decker, C. F., 1107
De Clercq, E., 18
Deelder, A. M., 1232, 1242
de Goede, R. E. Y., 349
de Groot, R., 1148, 1498
de la Durantaye, R., 1034
Delahunty, T., 273
Delanay, K., 1034
Delaney, S. F., 1092
de Lellis, L., 542
Delgado, K. L., 1273
DeMarsh, P. L., 203
de Moraes-Pinto, M. I., 1077
de Nijs, R., 460
Dennis, D. T., 1528
Dentener, M. A., 252
Deresinski, S. C., 677, 750
De Santis, C., 472
Detels, R., 1477
Detmer, J., 727
Dewar, R., 840
Dhumeaux, D., 511
Dias, F., 245, 263
Dickover, R. E., 1001
Diedrich, D. L., 226
Diehl, V., 1038
Diller, L., 256
Dillner, J., 1394
Dillon, M., 1001
Di Luca, D., 542
Dini, L., 1367
Doe, R., 877
Doenhoff, M. J., 1460
Dolan, M. J., 877
Dolcetti, R., 542
Dolin, R., 330, 340
Donnell, H. D., 1527
Donnelly, J. J., 314
Donsky, C., 1415
Doroshenko, E., 453
Dreitz, M., 187
Drew, W. L., 987
Drinevsky, V., 453
Drusano, G. L., 464, 1524
Duerr, A., 77
Dumler, J. S., 1027
Duncan, B., 997
Duncan, I. B., 1379
DuPont, H. L., 232
Eastman, D. J., 52
Eaton, K. A., 1288
Eberhard, T., 1137
Echeverria, P., 440, 1019
Edwards, K. M., 1256
Edwards, M. S., 142
Egan, A. F., 765
Ehrlich, G. D., 1072
Eickhoff, C. S., 285
Eisenach, K. D., 934
Elkins, M. M., 1097
Elkins, W. R., 829
Elliot, J., 365
Elliott, B. R., 1216
Ellis, D. H., 754
Ellis, R. W., 314
Ellner, J. J., 410
Emerson, S. U., 592
Emerson, T., 619
Engelhard, D., 735
Enscore, R. E., 781
Erban, J., 1164
Erice, A., 523
Erwin, M., 365
Escobedo, D., 1267
Escoffery, C., 718
Eskola, J., 136
Espevik, T., 259
Espinal, M. A., 488
Ettestad, P., 781
Eulálio, M. C., 758
Evans, L. A., 1092
Evans, T. J., 1399
Facchin, M., 684
Facklam, R. R., 365, 374
Faggioli, E., 1367
Falasca, L., 1367
Fallon, P. G., 1460
Falloon, J., 840
Farhat, C. K., 1077
Farley, M. M., 365
Farrell, J. P., 979
Farzadegan, H., 468
Fasano, A., 1019
Fast, P. E., 330
Fätkenheuer, G., 1038
Fattorini, L., 1030
Fauci, A. S., 60, 849
Feinberg, M., 476
Feinstone, S. M., 24
Feldman, J., 77
Feldmesser, M., 1222
Feller, M., 1171
Fennis, J. F. M., 460
Fernandez-Muñoz, R., 32
Ferreira, S. T. M. F., 1232
Ferretti, J. J., 901
Ferriero, D. M., 166
Fessel, J., 265
Fichtl, R. E., 1041
Fidel, P. L., Jr., 425
Field, H. J., 291
Fikrig, S., 1097
Filgueiras, T. E., 1077
Fink, L. M., 60
Firestone, C.-Y., 829
Fish, D., 187
Fleer, A., 212
Fletcher, T. W., 934
Flores, B. M., 226
Fontaine, C., 565
Forde, A. S., 1092
Forrest, B. D., 330
Fortier, M., 794
Fortney, K., 394
Fowler, M. G., 1097
Fox, C. H., 849, 1485
Francis, D. P., 52
Francot, G. J. M., 252
Frankel, R., 957
Franzen, C., 1038
Freedman, D. O., 1453
Freeman, J., 787
Freeman, W. R., 18, 1481
Freire, M., 758
Frey, C. L., 203
Frey, S. E., 330
Friedland, G., 1252
Frøland, S. S., 259
Frosch, M., 172
Frye, B., 1072
Fujihashi, K., 627
Fung, J. J., 1072
Gajadhar, A., 440
Galama, J. M. D., 460
Galetto-Lacour, A., 1388
Galgiani, J. N., 499, 1273
Gallant, J. E., 219, 505
Ganem, D., 248
García-Samaniego, J., 509

Garner, R. B., 1252
Garratty, E., 1001
Gary, H., 453
Gary, H. E., Jr., 787, 1470
Gavrilov, A., 453
Gaydos, C. A., 957
Gazit, A., 927
Gebo, K. A., 857
Gekker, G., 1194
Gelber, R., 1097
Gelderman, M. P., 1202
George, S., 256
Gerrits, Y., 1171
Gershon, A. A., 450
Ghibelli, L., 1367
Giacobbe, K. D., 98
Giebink, G. S., 119
Gillitzer, R., 699
Giugni, T. D., 1062
Glass, R. I., 787
Gleich, G. J., 1277
Glesby, M. J., 1477
Glover, C., 1009
Goddard, E. A., 1320
González, J., 509
González-Lahoz, J., 509
Gooley, T., 1208
Goorin, A., 256
Goossens, H., 1445
Gopinath, R., 1510
Gorse, G. J., 285, 330, 340
Govindarajan, S., 592
Graber, J., 1297
Graham, B. S., 340
Graham, N. M. H., 504, 1477
Graninger, W., 1281
Grant, R. M., 248
Grayston, J. T., 1519
Graziosi, C., 849
Green, J. H., 480
Green, M. D., 1506
Greenberger, M. J., 159
Greenspan, D., 710
Greenspan, J. S., 710
Greenwood, B. M., 765
Grefte, A., 240
Gregory, T. J., 52
Griffin, D. E., 1320
Griffin, P., Jr., 1493
Griffin, P. M., 1263
Griffith, B. P., 1252
Groeschel, M. C., 739
Grogan, J. L., 1242
Groover, J. E., 1347
Gros, P., 565
Grossi, P., 1072
Gruber, W. C., 1313
Grumet, F. C., 265
Gryseels, B., 1232
Guderian, R. H., 773
Guerreiro, J., 1515
Guglielmo, B. J., 1292
Gulick, L., 68
Gump, D. W., 1347
Gunn, R. A., 1263
Gupta, R. K., 1493
Guttormsen, H.-K., 142
Haase, D. H., 1256
Hachem, R., 418, 495
Hackett, C. S., 1467
Hackett, S. P., 619
Hafner, R., 91
Hagan, J. B., 1277
Hählen, K., 1498
Ham, D. J., 1062
Hamada, S., 627, 1428
Hamilton, B., 410
Hamilton, J. R., 677, 750
Hamilton, R. G., 83
Hamlin, D. M., 787
Hammack, C., 1157
Hammerschlag, M. R., 957
Hammerschmidt, S., 172
Hanchard, B., 718
Hänggi, M., 1379
Hanson, C. V., 330
Harb, G. E., 273
Harima, Y., 997
Hariprashad, J., 1041
Harmsen, W. S., 446
Harper, M., 870
Harrer, E., 476
Harrer, T., 476
Harrigan, P. R., 1354
Harrison, C. J., 1
Hart, C. A., 1077
Hashemi, F., 1085
Haslett, P. A. J., 1336
Hatano, N., 1115
Haubrich, R. H., 942
Haug, C. J., 259
Havlir, D. V., 942
Hawkes, C. A., 1523
Hawley, W. A., 1284
Hayashi, K., 1115
Hazelzet, J. A., 1148
Heath, J. L., 1470, 32
Hedlund, K.-O., 1062
Heimer, R., 997
Helfand, R. F., 1470
Hellewell, P. G., 1460
Hellyer, T. J., 934
Hendricks, K. A., 1263
Henning, K. J., 1263
Hepatitis-HIV Spanish Study Group, 509
Hertz, M. I., 1304
Herva, E., 387
Heyderman, R. S., 172
Hinshaw, L., 619
Hirsch, M. S., 355
Hirschel, B., 1294, 1388
Hitchcock, M. J. M., 987
Hjelle, B., 781
Hlady, W. G., 1176
Hlaváčová, B., 374
Ho, M., 1477
Ho, M. K.-L., 1009
Hoffner, S., 263
Hofheinz, D., 1523
Høgåsen, K., 647
Hohmann, E. L., 1408
Holder, A. A., 765
Hollingshead, S. K., 896
Holloway, B. P., 1284
Holman, R. C., 1297
Holodniy, M., 849
Honkanen, P. O., 387
Hood, A. F., 394
Hoover, D. R., 468, 504, 1477
Hop, W. C. J., 1148
Hopkins, D. P., 1263
Houghton, R. L., 758
Howard, R., 1273
Hsieh, R.-H., 330
Hsu, H. W., 870
Hu, S., 1194
Hubbard, B. S., 722
Hughes, J., 1320
Huguet, M.-F., 565
Humphrey, C. D., 787
Hurren, L., 1092
Hussey, G. D., 1320
Hutton, N., 1097
Huycke, M. M., 743
Ieven, M., 1445
Ilstrup, D. M., 446
International HCV Collaborative Study Group, 727
Ison, C. A., 172
Israel, E., 1260
Ivakhov, I., 453
Jabs, W. J., 1248
Jacewicz, M. S., 1164
Jackson, L. A., 1023
Jackson, R. J., 627
Jacobs, R. A., 1292
Jacobsen, H., 1379
Jacobson, M. A., 273
Jacobus, D. P., 1044
Jaffar, S., 245
Jahn, G., 240
Jain, R. C., 669
Janigan, D., 484
Janoff, E. N., 778
Jansen, A., 565
Jansen, K. U., 314
Jariwala-Freeman, B., 997
Jarvis, W. R., 656, 1293
Jay, M., 781
Jayaraman, K., 769
Jenkins, E., 656
Jero, J., 136
Jew, L., 550
Jhung, J. W., 1415
Jimenez, E., 1097
Jin, L., 32
Jobe, O., 245
Johnson, J. R., 746, 920
Johnson, P. M., 1077
Johnson, R. P., 476
Johnson, W. D., 1515
Jordan, M., 1292
Jordan, M. C., 523, 1304
Joyce, W., 743
Jungi, T. W., 971
Kagan, J., 1336
Kager, P. A., 1506
Kalbacher, H., 1051
Källenius, G., 263
Kallings, I., 1394
Kapur, V., 196
Karma, P., 136
Karron, R. A., 44
Kartalija, M., 1216
Kaslow, D. C., 765
Kasper, D. L., 142
Katongole-Mbidde, E., 248
Katzenstein, D., 1336
Katzenstein, D. A., 1005
Kawano, Y., 1115
Kaye, K., 1216
Käyhty, H., 136
Kebede, S., 1470
Keefer, M. C., 330, 340
Keitel, W., 453
Kelleher, A. D., 321
Kemper, C. A., 677, 750
Kendal, A., 453
Kenj, G., 1077
Kerran, M., 1320
Keruly, J. C., 219, 857
Kessler, H., 1085
Kesson, A. M., 7
Ketter, N., 330
Ketterer, M., 636
Keusch, G. T., 1164
Khabbaz, R. F., 1297
Khan, A. S., 453, 1297
Khoshnood, K., 997
Kierulf, P., 647
Kilgore, P. E., 787
Killeen, K. P., 1408
Kim, G., 1252
Kim, Y. S., 166
Kimani, J., 950, 1437
Kindt, T. J., 722
King, G. E., 32
King, J. C., 1313
Kinghorn, I., 1354
Kioski, C., 781
Kippen, D. A., 1023
Kira, J., 1115
Kirchner, H., 1248
Kita, H., 1277
Kiyono, H., 627, 1428
Klein, N. J., 172
Klontz, K. C., 1176
Kludt, P. E., 787
Klüter, H., 1248
Kluytmans, J. A. J. W., 914
Kobayashi, T., 1115
Koelle, D. M., 491
Koff, W. C., 330
Köhler, H., 512
Koivula, T., 263

Kolberg, J., 727
Kolls, J. K., 432
Konstan, M. W., 514
Koot, M., 349
Kootstra, N. A., 349
Kopp, J. B., 1485
Köppen, S., 265
Korhonen, T. K., 1137
Kornelisse, R. F., 1148, 1498
Korten, V., 1129
Korvick, J., 1336
Kosanke, S., 619
Koskela, P., 1394
Koster, F. T., 781
Kotb, M., 274
Kotylo, P., 394
Kovacs, J. A., 840
Kowalski, R., 68
Koyanagi, Y., 1115
Kozlow, E., 877
Krajčíková, L., 374
Krakowka, S., 1288
Krasinski, K., 574
Krausz, T., 1399
Krawczynski, K., 822
Kreiswirth, B. N., 196
Kremsner, P. G., 1242
Kriesel, J. D., 536
Kringstad, B., 1304
Krishna, S., 691
Ksiazek, T. G., 1297
Kubofcik, J., 773
Kumaraswami, V., 769
Kundu, S., 1336
Kundu, S. K., 1005
Kunkel, S. L., 159
Kuo, C.-C., 1519
Kuo, G., 822
Kuppermann, B. D., 18
Küppers, R., 1038
Kusne, S., 1072
Kuter, B. J., 731
Kuusela, P., 1137
Kyle, D. E., 691, 1506
Lacerda, L., 263
Lacke, C. E., 1347
Lafeuillade, A., 1522
Lahart, C. J., 1347
Lähteenmäki, K., 1137
Laichalk, L. L., 159
Lal, A. A., 1284
Lalezari, J., 849
Lalezari, J. P., 987
Lambert, S., 822
Lambert-Fair, M. A., 480
Lammel, C. J., 609
Landay, A. L., 1085
Landesman, S. H., 77
Landmann, R., 661
Lane, H. C., 840
Lane, J. R., 1523
Lange, J. M. A., 1354
Larder, B. A., 1354
LaRussa, P., 450
laSala, A., 1030
Laskay, T., 699
Latief, Z., 1320
Laue, N. W., 909
Laufer, D. S., 731
Lavandera, M., 488
Lavelle, J., 1354
Lavoie, M. C., 1034
Law, M. G., 1092
Le, C. T., 119
Leclercq, R., 1129
Lee, A. Y., 1009
Lee, F. K. N., 636
Lee, S.-D., 457
Lefkowitz, D. L., 1202
Lefkowitz, L., 1354
Lefkowitz, S. S., 1202
Lehtinen, M., 1394
Leib, S. L., 166
Leinonen, M., 128, 136, 387
Lennette, E. T., 710
Leno, M., 722
Leport, C., 91
Lesser, M. L., 68
Lévesque, D., 1034
Levin, M., 172
Levine, M. M., 1019
Levine, O. S., 579
Levine, W. C., 1263
Levitzki, A., 927
Levy, R., 1502
Lew, D., 800
Lewandowski, T. F., 203
Lewis, M. L., 499
Liang, Y. Y., 1260
Liao, M.-J., 1107
Liebeler, C. L., 119
Lien, E., 259
Linderholm, M., 38
Lindquist, E. A., 609
Liomba, G. N., 714
Liu, J., 901
Liu, M. A., 314
Liu, Q., 1216
Livingston, D. J., 1525
Lo, S. H., 450
Lobel, H. O., 1506
Lonskaya, N. L., 453
Looareesuwan, S., 1281
Lottenbach, K., 1014
Lu, M.-L., 574
Luber, A. D., 1292
Luft, B. J., 91
Lukehart, S. A., 491
Lundeberg, J., 992
Lundergan, L. L., 1273
MacDonald, K., 1437
Mach, M., 1051
Maciel, M. A., 1453
Mack, M. E., 306
Maclean, I. W., 950, 1437
Madureira, C., 758
Maenza, J. R., 219
Magnano, A. R., 480
Mahanty, S., 769
Maia e Silva, M. C., 1453
Maitha, G. M., 950, 1437
Makhene, M. K., 44
Makin, K. M., 1288
Malone, J. L., 1107, 1523
Mamelok, R. D., 1208
Mandema, J. W., 273
Manez, R., 1072
Mani, C., 1
Manns, A., 718
Mansouri, M., 418
Mao, C., 870
Mapou, R. L., 1107
Maras, B., 684
Marcotte, H., 1034
Mårdh, P. A., 1394
Margolick, J. B., 468
Marinaro, M., 627
Markowitz, L. E., 1320
Marrie, T. J., 484
Marthas, M. L., 1327
Martin, J., 300
Martinez, D., 314
Mas, A., 509
Masaki, T., 24
Mascola, J. R., 340
Massó, F., 1047
Masters, E. J., 1527
Masur, H., 840
Mattei, M., 1030
Matthews, T., 52
Matthews, T. J., 330
Mattsson, E., 212
Mauch, P., 256
Maupin, G. O., 403
Mayers, D. L., 1523
Mayur, R., 472
McCarter, R., 1260
McCarthy, J. S., 1510
McChesney, M. B., 1327
McCutchan, F. E., 340
McCutchan, J. A., 942
McDaniel, L. S., 380
McElrath, M. J., 340
McGhee, J. R., 627, 1428
McGillicuddy, D. C., 159
McGrath, N., 1097
McIntosh, K., 870, 1097
McKinnis, R., 1354
McMahon, D., 849
McNeil, J. G., 340
McQueen, P. W., 1092
McSherry, G., 1097
McVeigh, A., 1019
Meeks, E., 822
Mehra, N. K., 669
Meier, J. D., 119
Meier, P., 450
Meisels, A., 794
Melcher, G. P., 877
Mellors, J. W., 1252
Meltzer, M. S., 1107
Merigan, T. C., 1005, 1336
Merrill, D. P., 355
Mervish, N., 450
Merz, W. G., 219
Metcalf, J. A., 840
Metzger, W., 1242
Meyaard, L., 460
Michie, C. A., 274
Miedema, F., 460
Mikloska, Z., 7
Miller, G., 1297
Miller, S. I., 1408
Milligan, P. J. M., 1077
Miner, R., 987
Mink, C. M., 1014
Miotti, P. G., 714
Miralles, G. D., 60
Miro, J., 91
Mitchell, C. D., 1097
Mitchell, L. A., 1009
Modansky, M., 365
Modern, P. A., 98
Moguilevsky, N., 1202
Molina, J., 1019
Molitor, T. W., 1194
Moll, H., 699
Möller, E., 1062
Mollis, S. N., 769
Mollnes, T. E., 647
Molrine, D. C., 256
Monroe, S. S., 787
Montaño, L. F., 1047
Montecalvo, M., 1293
Montefiori, D. C., 60
Montgomery, D. L., 314
Montoya, J. G., 265
Moodie, J., 1320
Moonis, M., 355
Moore, M., 1354
Moore, R. D., 219, 237, 505, 857
Moran, E. E., 1157
Mordmüller, B., 1242
Morin, C., 794
Morlat, P., 91
Morris, J., 765
Mosley, D. G., 781
Mostowski, H., 863
Mous, J., 1379
Mouton, J. W., 914
Moyes, D., 1399
Mshar, P., 480
Mueller, B. U., 1485
Mueller, N. E., 584
Mukherjee, S., 1222
Mulder, J. W., 1354
Mulder, P. H. G., 1498
Müller, A., 1038
Müller, F., 259
Müller, S., 512
Mundy, L. M., 237
Munguia, D., 18
Murphy, B. R., 44, 829
Murphy, D., 863
Murray, B. E., 1129

Murray, H. W., 762, 1041
Murthy, K. K., 52
Musher, D. M., 83, 1347
Musser, J. M., 128, 196
Myers, M. G., 1
Myneedu, V. P., 669
Nabors, G. S., 979
Nagelkerke, N. J. D., 950, 1437
Nahlen, B. L., 1284
Nahm, M. H., 113
Nakagawa, I., 627, 1428
Nakamura, G. R., 52
Nakamura, M., 1115
Nakamura, T., 1115
Nakazawa, T., 24
Napolitano, B., 68
Nara, P., 512
Nasio, J. M., 491
Naso, R., 1157
National Institute of Allergy and Infectious Diseases Mycoses Study Group, 499
Nauclér, A., 245, 263
Navas, S., 300
Neice, C. M., 1460
Neijens, H. J., 1498
Nelson, K. E., 83, 579, 1490
Netto, E. M., 758
Neustock, P., 1248
Newman, F., 1313
Newman, F. K., 285
Newman, M., 24
Ngom, P. T., 245
Niang, M., 1232
Nichol, S. T., 1297
Nielsen, K., 1001
Nieminen, T., 136
Niesters, H. G. M., 1445
Nimmo, G., 754
Nishioka, M., 24
Niu, M., 849
Nizet, V., 180
Noah, T. L., 1050
Noel, J. S., 787
Nomura, A., 1474
Norberg, R., 263
Novak, R., 849
Novogrodsky, A., 927
Numazaki, K., 503
Nutman, T. B., 769, 773, 1277, 1510
Obijeski, J. F., 52
O'Brien, E., 1519
O'Brien, T. R., 1521
Ochnio, J. J., 1009
Odeberg, J., 992
O'Farrell, N., 1520
Ohrt, C., 1506
Okayama, A., 584
Okhuysen, P. C., 232
Olander, J. V., 113
Olariu, R., 432
Oldach, D., 237
Oletta, C. A., 1408
Oliveira, D. A., 1284
Oloo, A. J., 1284
Olson, C. A., 1304
Opal, S. M., 1157, 1415
Orazi, A., 394
Orefici, G., 1030
Orenstein, J. M., 849
Ostovic, E. J. R., 203
O'Toole, C., 512
Otsyula, M. G., 1327
Ott, M., 1379
Otten, M. F., 739
Ottesen, E. A., 769, 1277, 1510
Otto, E. E., 285
Owen, S., 1379
Oyugi, J., 1437
Padian, N. S., 1521
Paéz, A., 1047
Pahwa, S., 68
Palardy, J. E., 1415
Palefsky, J. M., 710, 718
Pande, J. N., 669
Pandey, J. P., 1347
Pantaleo, G., 60, 849
Paoletti, L. C., 142
Papaevangelou, V., 574
Pappagianis, D., 499
Pardo, M., 300
Parejo, N. A., 1415
Park, L. P., 504
Parredes, W. Y., 773
Parsonnet, J., 98
Partaledis, J. A., 1525
Patel, R., 446
Patton, D. L., 957, 1519
Patya, M., 927
Pau, B., 565
Paul, M. O., 68
Pavia, A. T., 656
Pavlakis, G. N., 849
Pawlotsky, J.-M., 511
Paya, C. V., 446
Pazhanisamy, S., 1525
Peakman, M., 172
Pearce, E. J., 269
Pediatric AIDS Clinical Trials Group, 1097
Pediatric Care Center, 44
Pedral-Sampaio, D., 758
Peeling, R. W., 1437
Peer, G., 619
Peña, C., 1260
Penaranda, M.-E., 710
Penfold, M. E. T., 7
Peng, T., 499, 1273
Penney, K., 957
Pennington, K. N., 1354
Pensart, N., 1129
Perneger, T. V., 1388
Perrin, L., 1388
Peterhans, E., 971
Peters, C. J., 1297
Peterson, P. K., 1194
Peveri, P., 971
Pfeiffer, T., 754
Phair, J. P., 1477
Phillips, N. R., 256
Piedra, P. A., 1313
Pier, G. B., 513
Piesman, J., 403
Piette, J., 1045
Pipitaporn, B., 691
Piscitelli, S. C., 840
Pizzo, P. A., 1485
Plachter, B., 240
Placido, R., 1367
Platt, R., 963
Plummer, F. A., 491, 950, 1437
Poggi, C., 1522
Polak, J., 1399
Polezhaev, F., 453
Polis, M. A., 840
Pollack, H., 574
Pomerantz, R. J., 550
Porath, A., 1502
Portela, D. F., 446
Porter, D. D., 598
Portmore, A., 265
Powell, M. F., 52
Powers, D. C., 285, 1014, 1467
Prince, A. M., 808
Prince, G. A., 598
Proctor, R. A., 739
Profizi, N., 1522
Pueyo, S., 91
Pugh, E., 1273
Pukrittayakamee, S., 691
Purcell, R. H., 592
Pursley, M., 18
Quartey, M. K., 119
Quinn, T. C., 957
Quint, W., 1445
Quirinale, J., 472
Quirk, M. R., 523, 1304
Quiroga, J. A., 300
Raad, I., 418, 495
Raeder, R., 888
Rager, J. R., 1263
Rajalingam, R., 669
Rakovsky, J., 374
Ralph, B. A., 380
Ramachandran, R., 1005
Ramirez, T., 1047
Ramirez-Ronda, C., 1354
Ramisse, F., 1123
Raoult, D., 484
Rappocciolo, G., 472
Rattray, C., 718
Ravichandran, M., 769
Razzouk, B. I., 529
Readdy, T. L., 896
Reber, A. M., 661
Reddington, C., 870
Reed, G. W., 1256, 1313
Reed, S. G., 559, 758
Reef, S., 1297
Regnery, H., 453
Regnery, R. L., 1023
Reichler, M. R., 374
Reingold, A. L., 488
Reis, N., 1273
Relman, D. A., 440
Remington, J. S., 265
Rennels, M. B., 306
Reynes, J., 565
Reynolds, P., 781
Ricard, D., 245
Rice, L. B., 151
Rice, P. A., 636
Rich, E. A., 1046, 1267
Riesenberg, K., 1502
Rigaud, M., 574
Riley, E. M., 765
Rinaldo, C., 1072
Risseeuw-Appel, I. M., 1148
Ritter, U., 699
Rivera, R., 1493
Robbioni, P., 472
Robertson, B. H., 822
Robinson, N. J., 1526
Roblin, P. M., 957
Rocchi, G., 1367
Rochford, G., 574
Rodriguez-Barradas, M. C., 83, 1347
Rodriguez-Iglesias, M. A., 1519
Rollin, P. E., 1297
Rollof, J., 212
Roman, S., 950
Rooney, J. F., 1354
Roorda, P., 1171
Roos, M. T. L., 460
Rosales, F. J., 507
Rosenthal, D. S., 787
Ross, A. C., 507
Rossi, C. A., 237
Rota, J. S., 32
Rota, P. A., 32
Rotmans, J. P., 1232
Rouse, M. S., 909
Rousseau, F., 91
Roy, M., 794
Rubens, C. E., 180
Rubinstein, A., 1097
Ruf, B., 265
Ruiz, N. M., 1523
Ruiz, V., 1047
Ruma, P., 754
Rumpold, H., 1281
Ryan, I., 550
Ryon, J. J., 1320
Saah, A. J., 468, 504, 1477
Sabin, E. A., 269
Sada, E., 1267
Sadoff, J. C., 1157, 1422
Šadžiene, A., 1184
St. Clair, M., 1354
St. George, K., 1072
Salamon, R., 91
Salanitro, A., 1367
Salhi, S. L., 565
Salmón, L. E., 1047

Salmon-Céron, D., 1045
Salzberger, B., 1038
Salzman, N. P., 840
Sample, C. E., 529
Sande, M. A., 1216
Sands, K., 963
Sands, L., 781
Sankilampi, U., 387
Sansano, S., 661
Santos, A. M. N., 1077
Sapp, M., 1394
Sappey, C., 1045
Sarisky, J., 781
Savarino, S. J., 1019
Savelkoul, H. F. J., 1148, 1498
Sayed, R., 1320
Sayers, M. H., 1023
Schachter, J., 957
Schiffman, M. H., 718
Schiller, J. T., 1394
Schlaeffer, F., 1502
Schlievert, P. M., 1290
Schmidt, K. A., 1422
Schmidt, T. M., 440
Schneider, H., 1422
Schnittman, S., 849
Schonberger, L. B., 453
Schönthal, E., 1281
Schooley, R. T., 1354
Schrappe, M., 1038, 265
Schriefer, M. E., 1528
Schuchat, A., 365
Schuitemaker, H., 349
Schulhoff, N., 957
Schumacher-Perdreau, F., 265
Schwander, S. K., 1267
Schwartz, D. H., 340
Schwartzentruber, D. J., 1485
Sei, S., 1485
Semba, R. D., 509
Semenuk, M., 1157
Sethabutr, O., 440
Settergren, B., 38
Sewell, C. M., 781
Shah, K. V., 714
Shamberger, R. C., 256
Shani, J., 957
Shapiro, M., 592
Shay, D. K., 1293
Shearer, G. M., 1085, 472
Sheiner, L. B., 273
Shellito, J. E., 432
Shen, C., 950
Shi, Y. P., 1284
Shinkai, M., 1481
Shirabe, S., 1115
Shirai, M., 24
Shiratsuchi, H., 410
Shlaes, D. M., 151
Shohami, E., 735
Shriker, O., 1502
Siber, G. R., 113, 1493
Siccardi, A. G., 472
Sierra, J. G., 1267
Sierra, M. F., 77
Sikström, B., 1394
Simmonds, P., 727
Simonetti, N., 684
Simpson, R. M., 722
Singh, V., 529
Sinha, S., 822
Sinzger, C., 240
Sirisanthana, T., 1490
Sison, J. P., 677, 750
Sixbey, J. W., 529
Skillman, D. R., 1107, 1422
Skurnick, J. H., 1521
Sláčiková, M., 374
Smith, A. L., 180
Smith, D. B., 727
Smith, G. E., 1336, 1467
Smith, I. L., 1481
Smith, T., 275
Smith, T. F., 446
Snyder, S. W., 340
Sobel, J. D., 425
Sobotová, A., 374
Söderberg, C., 1062
Sogin, M., 440
Sominina, A., 453
Sönnerborg, A., 992
Soriano, V., 509
Sorrell, T. C., 754
Sotir, C. M., 896
Spach, D. H., 1023
Spector, S. A., 1481
Speed, B. R., 754
Spelbring, J. E., 822
Spino, C., 1336
Spinola, S. M., 394
Spruance, S. L., 536
Srinivas, S., 529
Sriskandan, S., 1399
Staehle, B., 731
Stamm, W. E., 1023
Stanberry, L. R., 1, 800
Standiford, T. J., 159
Stanley, S. L., Jr., 226
Stead, W. W., 934
Steckelberg, J. M., 909
Steel, H., 1354
Steers, J. L., 446
Steigbigel, R. T., 849
Stein, A., 484
Stein, D. S., 464, 504
Steinberg, S., 450
Steinhoff, M. C., 44, 83
Stellrecht, K., 464
Stelma, F. F., 1232
Stemmermann, G. N., 1474
Stephens, D. S., 365
Stephens, L. C., 495
Stephens, R. S., 609
Sterling, C. R., 232
Stevens, D. A., 677, 750
Stevens, D. L., 619, 901
Stewart, D., 1519
Stratton, C. W., 909
Strebel, P. M., 1320
Strickland, G. T., 1260
Strickler, H. D., 718
Strieter, R. M., 159
Strine, T., 1297
Stringaro, A., 684
Stuver, S. O., 584
Stuyver, L., 511
Subbarao, K., 44
Sugg, N. K., 1023
Sukhai, R. N., 1498
Sundar, S., 762
Supparatpinyo, K., 1490
Suputtamongkol, Y., 691
Suur, M. H., 1148, 1498
Suzuki, J., 1115
Suzuki, Y., 265
Svenson, S., 263
Swanink, C. M. A., 460
Swiatlo, E., 777
Swiss HIV Cohort Study Group, 1388
Szatanik, M., 1123
Tabor, E., 1474
Tachibana, N., 584
Tait, L., 425
Takahashi, I., 1428, 627
Takala, A. K., 128
Talla, I., 1232
Tamalet, C., 1522
Tankersley, D. L., 822
Tappero, J., 1297
Tarara, R. P., 1327
Tarbell, N. J., 256
Tarina, P., 374
Tarkka, E., 128
Tärnvik, A., 38
Tart, R. C., 380
Täuber, M. G., 1216, 166
Tauxe, R. V., 480
Tawadros, R., 550
Taylor, R., 1157
Tedder, R. S., 245
Teichert, M., 1194
Teixeira, M. M., 1460
Teltow, G. J., 403
Templeton, G. L., 934
Tendeloo, D. C. H., 1506
Tersmette, M., 349
Testa, D., 1107
Tetali, S., 68
Thackray, A. M., 291
The, T. H., 240
Theis, J., 1273
Thompson, C., 1493
Thompson, P. A., 1184
Tierno, P. M., Jr., 1289
Tjhie, J. H. T., 914
Tobias, W., 1077
Todd, G. D., 1506
Toossi, Z., 410
Torian, B. E., 226
Torres, M., 1267
Torrez-Martinez, N., 781
Torriani, F. J., 942
Tosi, M. F., 514
Treanor, J. J., 1313, 1467
Trembovler, V., 735
Tsarev, S. A., 592
Tung, R. D., 1525
Tureen, J. H., 1216
Tytgat, G. N. J., 1171
Udomsangpetch, R., 691
Uhlén, M., 992
Ullberg, M., 1137
Urbani, F., 1030
Urdea, M., 727
Ursi, D., 1445
Vahey, M. T., 877, 1523
Valentine, F. T., 1336
van Alphen, L., 1137
van Ameijden, E. J. C., 1506
Van Bever, H., 1445
van Burik, J.-A., 1208
Vance, E., 237
van Dam, G. J., 1232, 1242
Van Delden, C., 1294
Van der Auwera, P., 1129
van der Ende, A., 1171
van der Heijden, A. J., 1498
van der Hulst, R. W. M., 1171
van der Meer, J. W. M., 460
van der Straaten, P. J. C., 1498
van der Ven-Jongekrijg, J., 460
van der Voort, E., 1148
Van Devanter, N. L., 1521
Van De Verg, L., 1422
Van Dijk, H., 212
van Embden, J. D. A., 196
van Gool, T., 1506
Vanichkin, A., 927
Van Kessel, K., 212
Vann, J. M., 739
Vannaphan, S., 1281
Van Rompay, K. K. A., 1327
van Soolingen, D., 196
van Thiel, P. P. A. M., 1506
van 't Wout, A. B., 349
Van Voorhis, W. C., 491
Vasile, L. L., 480
Vasiljeva, R., 453
Vasquez, M., 1336
Velazco, O., 699
Vella, S., 1379
Veltink, R. L., 1506
Vendrell, J.-P., 565
Vennari, J. C., 52
Ventura, L., 1367
Venzon, D. J., 1485
Verbrugh, H. A., 914
Vercoulen, J. H. M. M., 460
Verhoef, J., 212
Verma, P., 656
Vesga, O., 739
Vetten, B., 1038
Vildé, J.-L., 91, 1045
Villa, M. L., 472
Vineyard, G., 963

Virkola, R., 1137
Virolainen, A., 136
Vlahov, D., 509, 579
von Laer, D., 503
Voorhees, R. E., 781
Vuong, C., 18
Vuopio-Varkila, J., 128
Waage, A., 38
Wachter, H., 971
Wack, M. F., 743
Wafer, D., 1001
Wagner, H. J., 1248
Wagner, K. F., 1107, 340
Wagner, O., 1281
Walker, B. D., 476
Walker, M. C., 340
Walker, R. E., 840
Wang, S.-P., 1519
Wang, X. P., 68
Wang, Y.-F., 808
Ward, R. L., 306
Warner, M. L., 237
Warren, R. L., 1422
Watson, B. M., 731
Watson, J., 1019
Weel, J. F. L., 1171
Wei, L. S., 1001
Weiland, O., 992
Weinberg, E. D., 1045
Weinberg, G. A., 1045
Weinhold, K. J., 330
Weintrub, P. S., 1097
Weislow, O. S., 340
Weiss, S. H., 472
Weiss, S. M., 957
Weiss, W., 276
Wellcome Resistance Study Collaborative Group, 1354
Wells, G. I., 203
Weng, S., 1477
Wenisch, C., 1281
Wenisch, H., 1281
Werner, E. R., 971
White, C. J., 731
White, N. J., 691
Whittle, H., 245
Wieden, M. A., 1273
Wiesner, R. H., 446
Wilairatana, P., 1281
Wiley, C. A., 18
Wilfert, C. M., 1097
Wilkins, A., 245
Wilkinson, B. E., 1467
Williams, D. L., 196
Williams, S. A., 1510
Williams, T. J., 1460
Wills, M. J., 1256
Wilson, M. H., 44
Wilson, W. R., 909
Winqvist, N., 263
Winters, M. A., 1005
Wong, M. T., 877
Wong, S.-Y., 265
Woods, M. L., 656
Wright, P. F., 1313, 44
Wrin, T., 52
Wu, J.-C., 457
Wyeth-Ayerst CA Influenza Vaccine Investigators Group, 1313
Wylie, H. J., 1422
Xiao, Y., 1030
Xu, J., 1493
Yamamoto, N., 1115
Yamasaki, K., 1115
Yang, C., 950
Yang, L.-P., 714
Yang, W., 226
Yao, Y., 677, 750
Yap, P.-L., 727
Yazdanbakhsh, M., 1242
Yen, F.-S., 457
Yerly, S., 1388
Yoder, K., 440
Yogev, R., 1097
Yong, T.-S., 226
Young, L. D., 1157, 1415
Yun, Z. B., 992
Yzerman, E. P. F., 914
Zaia, J. A., 1062
Zaki, S. R., 1297
Zaunders, J., 321
Zeidner, N., 187
Zermeno, A., 495
Zhao, Q., 609
Zheng, N. N., 1092
Zhong, M., 1510
Zhou, D., 636
Zhou, J. T., 60
Zhou, J. Y., 60
Zhou, S. Y. J., 1523
Zimmerli, W., 661
Zito, E. T., 306
Zollinger, W. D., 1157
Zolopa, A. R., 265

Subject Index

1,25 dihydroxyvitamin D, in disseminated MAC infection, in AIDS, 259
β-lactam–β-lactamase inhibitor combinations, *K. pneumoniae* resistance, 151
Acyclovir
  for HIV infection, survival in, 504, 505
  for neonatal HSV infection, 1
  risk for Kaposi's sarcoma, Multicenter AIDS Cohort study, 1477
Adherence
  H. influenzae, to mammalian extracellular matrix, 1137
  P. falciparum, and rosetting, 691
Adhesins, *E. coli,* PCR detection of *papG,* 920
AIDS (*See* human immunodeficiency virus infection)
AIDS Clinical Trials Group
  HIV envelope vaccine, protocol 137, 1336
  pediatric infection, low-dose zidovudine for, protocol 128, 1097
American visceral leishmaniasis, IL-12 role in, 1515
Amocarzine, for *O. volvulus* infection, 773
Amphotericin B
  colloidal dispersion, for invasive fungal infection, in transplant recipients, 1208
  lipid complex, for visceral leishmaniasis, 762
Animal model
  B. burgdorferi, flagella-less mutant, as vaccine, in Lyme disease, mouse, 1184
  catheter, minocycline/rifampin coating, efficacy, rabbit, 418
  C. burnetti infection, acute, route, mouse, 484
  C. glabrata vaginitis, mouse, 425
  CMV retinitis, liposome-encapsulated cidofovir for, rabbit, 18
  E. coli
    enterotoxin, immunization, antibody response, 1428
    septic shock, prevention by tyrosine kinase inhibitor, mouse, 927
  GBS meningitis, kynurenic acid for, neuroprotective effect, neonatal rat, 166
  HCV infection, postexposure prophylaxis, chimpanzee, 822
  HIV-1 vaccine, chimpanzee, 52
  HSV infection, neonatal, antibody and acyclovir for, guinea pig, 1
  HSV-1, latency and reactivation, mouse, 291
  HSV-2 genital infection, DNA immunization against, guinea pig, 800
  HTLV-I pathogenesis, rabbit, 722
  K. pneumoniae infection, macrophage inflammatory protein for, mouse, 159
  L. donovani, relapse, mouse, 1041
  L. major, chemotherapy for, effect of polarity to T cell response, mouse, 979
  MAC infection, bacteremia, treatment, mouse, 750
  P. aeruginosa sepsis, neutropenic rat, immunotherapy for, 1415
  papillomavirus, DNA vaccine against, rabbit, 314
  parainfluenza virus type 3, bronchiolitis and pneumonia, treatment for, cotton rat, 598
  P. carinii
    pneumonia, in transgenic B cell–deficient mouse, 1034
    nitric oxide and host defense, mouse, 432
  Q fever, acute, infection route, mouse, 484
  S. pneumoniae
    otitis media, polysaccharide-protein conjugate vaccines for, chinchilla, 119
    pneumonia, immunotherapy for, leukopenic mouse, 1123
    PspA, cross-protection, mouse, 380
  S. pyogenes, necrotizing fasciitis, mouse, 1399
  UTI, ascending, inoculation conditions, mouse, 746
Antibody
  HLA class I, in HIV-negative, high-risk IDUs, 472
  neutralizing, against HIV-1, 340
  passive, for neonatal HSV infection, 1
Antibody to
  C. immitis, serologic diagnosis, 499
  Coccidioides, detection, for diagnosis, 1273
  E. coli enterotoxin, mouse model, 1428
  H. influenzae, transplacental transfer, in Mexican mothers, 1047
  HIV-1
    in cervicovaginal secretions, risk of viral transmission to infants, 1001
    response in long-term nonprogressors, 60
  HTLV-I *pX* gene mutant products, 1115
  N. meningitidis, in children and adolescents, 1009
  P. aeruginosa, in CF patients, 513, 514
  P. falciparum, 765
  pneumococcal vaccine, for HIV-1 infection, 83
  S. agalactiae type III capsular polysaccharide, 142
  S. mansoni, in recently-exposed Senegal community, 1232
  S. pneumoniae
    capsular polysaccharide, response, in elderly, 387
    in otitis media, in children, 136
APACHE II score, use in *S. aureus* bacteremia, to predict outcome, 914
Artemisinin derivatives, effect on *P. falciparum* adherence and rosetting, 691
Atherosclerosis, absence of *C. pneumoniae* coronary atheromas, 957

Bacteremia
  enterococcal, superoxide production in, 743
  GAS, TNF-α role, 619
  gram-negative, vaccine against, 1157
  H. influenzae, nonencapsulated, 180
  MAC, treatment, mouse model, 750
  S. aureus, nosocomial, APACHE II use in, 914
Bactericidal/permeability-increasing protein, on monocyte surface, 252
Bartonella quintana, seroprevalence, at community clinic, in Seattle, 1023
Big endothelin, in *P. falciparum* malaria, 1281
Bordetella pertussis, infection, seroepidemiology, in persons 1–65 years, 1256
Borrelia burgdorferi infection
  cytokines for, 187
  flagella-less mutant, as vaccine, in murine Lyme disease, 1184
  public health impact, in Maryland, 1260
Borrelia lonestari sp. nov., identification in hard tick *A. americanum,* 403
Borrelia species, epidemiologic and diagnostic studies, 1527, 1528
Bronchiolitis, parainfluenza type 3, treatment, cotton rat model, 598
Burkitt's lymphoma, EBV DNA loss in, 529

Candida albicans
  cell wall, and enolase, 684
  macrophage activity against, myeloperoxidase role in, 1202
Candida glabrata, vaginitis, mouse model, 425
Candida species, infection, oroesophageal, fluconazole resistance, in HIV infection, 219
Carcinoma, hepatocellular, association with HBV and HCV, in Japanese-Americans, 1474
Catalase-peroxidase gene, characterization, in *M. tuberculosis,* 196
Catheter
  minocycline/rifampin coating, efficacy, rabbit model, 418

silver iontophoretic, antiinfective prototype, 495
CD4 epitope masking, in HIV infection, 565
CD4-IgG, HIV-1 inactivation, 863
CD14 receptors, role in multinucleated giant cells, 1194
Ceftazidime, resistance, in *K. pneumoniae,* 151
Cervical infection, HPV, persistence, 794
Chancroid, host response, in human experimental infection, 394
Chemokines, in leishmaniasis, 699
Chlamydia infection, as risk factor for HIV infection, in women, 1520, 1521
Chlamydia pneumoniae infection, in coronary tissue, 957, 1519
Chlamydia trachomatis infection
PID, among sex workers in Nairobi, Kenya, 1437
serology, 609, 1394
in STD core group, epidemiology, 950
Chronic fatigue syndrome, immunologic diagnostic tests, 460
Cidofovir, for CMV, human, 987
Clofazimine, for MAC infection, 677
Coccidia, taxonomy, 440
Coccidioides immitis, meningitis, antibody detection, 499
Complement activation, *N. meningitidis,* septic shock, 647
Coronary atherectomy, *C. pneumoniae,* 1519
Coxiella burnetti, infection, route, mouse model, 484
Cryptococcus neoformans
interaction with murine macrophage-like cell, opsonin effect on, 1222
meningitis, experimental, fluconazole and flucytosine for, 1216
RAPD analysis, in immunosuppressed patients, 754
Cryptosporidium parvum, infection, intensity and oocyst excretion patterns, 232
Cyclospora, molecular genetic analysis, relation to *Eimeria,* 440
Cystic fibrosis, *P. aeruginosa,* antibody in, 513, 514
Cytokines
HFRS, 38
measurements, in nasal lavage fluid, markers of dilution, 1049, 1050
in syphilis, 491
Cytomegalovirus infection
cidofovir susceptibility, 987
ganciclovir resistance, CNS disease, 1481
of hematopoietic cells in tissue, 240
in HIV-1–infected and –uninfected women, 77
of leukocytes, 503
neutralization by CD13-specific antibody, 1062
PCR detection, predictor of CMV disease, 1072
pneumonia, diagnosis, 1297
resistance, ganciclovir, 523
retinitis, liposome-encapsulated cidofovir for, rabbit model, 18
T cell response to, 1051
viremia, in liver transplant recipients, prognostic significance, 446
Cytotoxic T lymphocytes
against HCV, 24
in HIV infection, in long-term nonprogressor, 476

Didanosine for HIV infection
and IFN-α, phase I/II trial, 840
in multidrug combinations, 355
population pharmacokinetics, 273
virus phenotype changes, 1092
and zidovudine or zalcitabine and zidovudine combination therapy, vs. zidovudine monotherapy, 1354
Diethylcarbamazine, for onchocerciasis, posttreatment eosinophilia, 1277
Diphtheria, antitoxin, in US blood and plasma donors, 1493
DNA recombination, EBV, in Burkitt's lymphoma, 529

Ehrlichia equi, infection, and antibody, 1027
EIA to detect
HBV and HCV, in syringes, 997
measles virus, 1470
Elephantiasis, *W. bancrofti,* cytokines in, 1453
ELISA to detect
C. immitis spherule antigen, in CSF, 499
Coccidioides antibody, 1273
GBS III capsular polysaccharide–specific IgM antibody, 142
S. pneumoniae capsular polysaccharide antibody, 113
Encephalitis
T. gondii, in AIDS, genetic regulation of susceptibility, 265
Toxoplasma
folic acid supplements to pyrimethamine-sulfadiazine for, 1294
in HIV infection, pyrimethamine prophylaxis, 91
Endocarditis, *E. faecium,* vancomycin-resistant, cell wall–active agents for, 909
Endothelial injury, by *N. meningitidis,* 172
Enolase, in *C. albicans* cell wall, 684
Entamoeba histolytica, alcohol/aldehyde dehydrogenase, 226
Enterococci
glycopeptide resistance, natural reservoir in healthy persons, 1129
vancomycin, oral vs. iv administration, resistance development, 1292, 1293
Enterococcus faecalis, superoxide, extracellular, production, 743
Enterococcus faecium, endocarditis, vancomycin-resistant, cell wall–active agents for, 909
Enterotoxin
E. coli
heat-stable, distribution among *E. coli,* 1019
immunization, systemic and mucosal antibody response, 1428
mucosal immunogenicity of, 627
staphylococcal, food poisoning, 1263
Epidemiology
B. burgdorferi infection, public health impact, in Maryland, 1260
B. pertussis antibody, in persons 1–65 years, 1256
B. quintana, seroprevalence, at community clinic, in Seattle, 1023
C. trachomatis infection
PID, among sex workers in Kenya, 1437
in STD core group, 950
E. coli O157:H7, outbreak, 480
hantavirus pulmonary syndrome, 237, 781, 1297
hepatitis, incidence, among IDUs, 579
hepatitis C, genotypes in Spain, 509, 511
HIV infection
cervicovaginal shedding, transmission risk to infants, 1001
incidence, among IDUs, 579
S. pneumoniae infection in, 857
HIV-2, provirus load, community-based study, in Africa
HPV
neoplasia, cervical, prevalence, in Jamaican women, 718
serology, markers of sexual behavior, 1394
HTLV-I morbidity, among carriers, in Japan, 585
Lyme disease, epidemiologic and diagnostic studies, 1527, 1528
measles virus, molecular, 32
M. tuberculosis, infection, pregnancy as risk factor for, in HIV infection, 488
pregnancy, risk factor for tuberculosis, in HIV infection, 488
small round-structured virus, gastroenteritis, outbreak, molecular investigation, 787
S. pneumoniae infection
in HIV infection, 857
resistant, spread in hospitalized children, in Slovakia, 374
Staphylococcus enterotoxin, food poisoning, canned mushrooms, 1263
surgical site infection, after hospital discharge, 963

Vibrio infections, in Florida, 1981–1993, 1176
Epstein-Barr virus
DNA recombination, in Burkitt's lymphoma, 529
sequence variation in LMP-1, in hairy leukoplakia, 710
seronegative adults, immunologic properties, 1248
Errata
Anzala et al., 1995;171:686–9, 1529
Bernard et al., 1994;170:1077–85, 516
Heneine et al., 1995;171:1210–6, 1529
Papillomavirus series, 1994;170:1075–99, 516
Rennels et al., 1996;173:306–13, 1529
Salmon-Ceron et al., 1995;172:656-64, 277
Tsai et al., 1995;171:1338-43, 277
Watson et al., 1996;173:731–4, 1529
Escherichia coli
enterotoxin
heat-stable, distribution among *E. coli,* 1019
immunization, oral, cytokine induction in, 1428
labile, mucosal immunogenicity of, 627
J5 LPS, vaccine, 1157
O157:H7, outbreak, 480
papG variants, PCR detection, 920
sepsis, hematoregulatory peptide SK&F 107647 for, 203
septic shock, prevention by tyrosine kinase inhibitor, mouse model, 927
Ethanol, effect on HIV replication, 550

Famciclovir, for HSV-1 infection, mouse model, 291
Farr assay, modified, to measure *S. pneumoniae* capsular polysaccharide antibody, 113
Fasciitis, necrotizing, *S. pyogenes,* 901
Filariasis due to *W. bancrofti*
cytokines in, 769, 1453
PCR detection, 1510
Fluconazole
for *C. neoformans* meningitis, experimental, 1216
resistance, in candidiasis, in HIV infection, 219
Flucytosine, for *C. neoformans* meningitis, experimental, 1216
Folic acid, supplements, to pyrimethamine-sulfadiazine, for *Toxoplasma* encephalitis, 1294
Foscarnet, risk for Kaposi's sarcoma, Multicenter AIDS Cohort study, 1477
Four Corners hantavirus, epidemiology, 781
Fungal infection, invasive, in transplant recipients, amphotericin B colloidal dispersion for, phase I study, 1208
Furunculosis, recurrent, vitamin C for, 1502

Ganciclovir
CMV resistance, CNS disease, 1481
risk for Kaposi's sarcoma, Multicenter AIDS Cohort study, 1477
Gastroenteritis, small round-structured virus, outbreak, molecular investigation, 787
Glucocorticosteroid, for parainfluenza type 3 bronchiolitis and pneumonia, cotton rat model, 598
Gonorrhea *(See Neisseria gonorrhoeae)*
GOR epitope, in chronic HCV infection, 300
Granulocyte-macrophage colony-stimulating factor, role in posttreatment eosinophilia, in onchocerciasis, 1277
Group A streptococcus, bacteremia, TNF-α role, 619
Group B streptococcus
antibody, naturally acquired, 142
disease, invasive, serotype V emergence, 365
meningitis, kynurenic acid for, neuroprotective effect, neonatal rat model, 166

Haemophilus ducreyi
adherence, to mammalian extracellular matrix, 1137
antibody, transplacental transfer, in Mexican mothers, 1047
host response, in human experimental infection, 394
nonencapsulated, virulent, 180
Hairy leukoplakia, sequence variation EBV LMP-1, 710
Hantavirus, HFRS, cytokine levels in, 38
Hantavirus pulmonary syndrome
genomic sequences, in rodents and humans, 781
incidence, in Baltimore, 237
US cases, 1297
Helicobacter pylori, coccoid forms, 1288
Helicobacter pylori–related diseases, virulence factors, 1171
Hemagglutinin, recombinant vaccine, against influenza, in adults, 1467
Hemorrhagic fever with renal syndrome, hantavirus infection, cytokine levels in, 38
Hepatitis
incidence, among IDUs, 579
in syringes, used, sensitivity of detection techniques, 997
Hepatitis A virus, vaccine, attenuated, simian strain protects chimpanzees, 592
Hepatitis B virus, mutants, in HDV superinfection, 457
Hepatitis B and C, hepatocellular carcinoma association, in Japanese-Americans, 1474
Hepatitis C virus
CTL, peptide vaccine for, 24
genotypes, in Spain, 509, 511
infection
GOR antibody in, 300
heterogeneity, during IFN-α therapy, 992
prophylaxis, postexposure, in chimpanzees, 822
serotypes 1–6, 727
structural proteins, immune response, in humans and chimpanzees, 808
Hepatitis D virus, superinfection, HBV mutants in, 457
Hepatocellular carcinoma, association with HBV and HCV, in Japanese-Americans, 1474
Herpes simplex virus
CD4 and CD8 lymphocyte cytotoxicity, 7
infection
neonatal, antibody and acyclovir for, guinea pig model, 1
type 1, latency and reactivation, mouse model, 291
type 2
genital, DNA immunization against, guinea pig model, 800
vaccine against, 536
type 8, Kaposi's sarcoma in, 248
Hodgkin's disease, pneumococcal conjugate vaccine, after treatment, 256
HU-211, nonpsychotropic cannabinoid, for *S. pneumoniae* meningitis, 735
Human granulocytic ehrlichiosis, cause of undifferentiated fever, 1027
Human herpesvirus 8, presence in lymphoid system, in AIDS, 542
Human immunodeficiency virus type 1 infection
acyclovir for, survival in, 504, 505
of alveolar macrophages, from smokers, iron and HIV replication in, 1045, 1046
antibody responses, in long-term nonprogressors, 60
antiretroviral monotherapy for, effect on virus load, 849
CD4 epitope concentration ratio, as marker of progression, 565
CD4-IgG inactivation and binding, 863
cell-associated virus load, and T lymphocytes, 468
cervicovaginal shedding, transmission to infants, risk, 1001
CMV infection in, in women, 77
CTL response, in long-term nonprogressor, 476

ddI for
HIV phenotype changes, 1092
and IFN-α for, phase I/II trial, 840
population pharmacokinetics in, 273
effect on antibody response to pneumococcal vaccine, 83
ethanol effect on replication, 550
gp120 vaccine, failure, mechanism of, 512
heterosexual transmission, 1520, 1521
HHV-8 reactivation in, 542
HLA class I antibodies, in high-risk seronegative IDUs, 472
and HPV infection, cervical abnormalities, 714
IFN-αn3 for, phase I trial, 1107
IL-2 effect on replication, 559
IL-12 and anti-IL-10 effects on T cell function, 1085
incidence, among IDUs, 579
induced cell death, prevention, 1367
in infants, determination of infection status, 68
iron supplementation in, 1044, 1045
lamivudine or stavudine multiple drug combinations for, 355
long-term, prognostic value of viremia, 1388
maternal, maternal-fetal transfer of IgG immunity, 1077
neutralizing antibody, 340
pediatric, 574, 1097, 1327, 1485
PEG–IL-2 and thymosin α[cf15]1 for, 1005
P. marneffei infection in, seasonal variation, in Thailand, 1490
pneumococcal
infection, in children, 870
vaccine in, 777, 778
prognostic parameters, 1522, 1523
progression, 877, 1526
protease inhibitors, 321, 1524, 1525
resistance, in vivo, to saquinavir, 1379
retinol levels in, 507, 507
S. pneumoniae infection in, epidemiology, 857
sTNFαRII in, 464
T. gondii encephalitis in, genetic regulation of susceptibility, 265
vaccine
chimpanzee model, 52
envelope subunit, 340
immune response, ACTG protocol 137, 1336
safety and immunogenicity, 330
virus load
phenotype, and clonal composition, 349
stavudine effect on, 1252
zidovudine and zalcitabine or ddI combination therapy vs. zidovudine monotherapy for, 1354
Human immunodeficiency virus type 2, infection, provirus load, community-based study, in Africa
Human papillomavirus infection
and cervical neoplasia, prevalence, in Jamaican women, 718
and HIV infection, cervical abnormalities in Malawi women, 714
persistence in cervix, 794
serology, markers of sexual behavior, 1394
Human T cell leukemia virus type I infection
morbidity, among carriers, in Japan, 585
pX gene mutant products, antibody to, 1115
rabbit model, 722

IgE antibody, to *S. haematobium,* response after chemotherapy, in adults and children, 1242
IgG
antibody, to pneumococcal capsular polysaccharide, in HIV infection, 1347
immunity, maternal-fetal transfer, HIV-infected mothers, 1077
IgG-binding proteins, *S. pyogenes,* 888
IgG4 antibody, to *S. haematobium,* response after chemotherapy, in adults and children, 1242
IgM EIA, to detect measles virus, 1470
Impetigo, *S. pyogenes,* genetic markers, 896
Infectious Diseases Society of America, Presidential Address, annual meeting, 517
Influenza A virus
PMNL dysfunction, 279
vaccine, 44, 285
Influenza virus vaccine
inactivated, split vs. live attenuated, in Russian schoolchildren, 453
live attenuated, safety, immunogenicity, and efficacy, in children, 1313
recombinant hemagglutinin, in adults, 1467
Interferon-α
and didanosine, for HIV infection, phase I/II trial, 840
for HCV infection, HCV heterogeneity during therapy, 992
production, in EBV-seronegative adults, 1248
Interferon-αn3, for HIV infection, phase I trial, 1107
Interferon-γ
for *B. burgdorferi* infection, 187
in *T. pallidum* phagocytosis, 491
Interleukin-2
for *B. burgdorferi* infection, 187
effect on HIV replication, 559
polyethylene glycol–modified, for HIV infection, 1005
Interleukin-5, role in posttreatment eosinophilia, in onchocerciasis, 1277
Interleukin-6
levels in HFRS, 38
production, in EBV-seronegative adults, 1248
Interleukin-8, release, in response to sCD14 and LPS, 661
Interleukin-10
in CSF, of children with bacterial meningitis, 1498
production, in human lymphatic filariasis, 769
role, in growth in *Mycobacterium avium,* 410
Interleukin-12
effect on T cell immune function, in HIV-infected persons, 1085
in visceral leishmaniasis, IL-12 role in, 1515
Iron
and oxidative stress, effect on HIV replication, 1045, 1046
supplementation, in HIV infection, 1044, 1045
Isoniazid resistance, in *M. tuberculosis,* 196

Kaposi's sarcoma
herpesvirus in, 248
risk factors, Multicenter AIDS Cohort study, 1477
Klebsiella pneumoniae infection
ceftazidime resistance in, 151
macrophage inflammatory protein for, mouse model, 159
resistance, to β-lactam–β-lactamase inhibitor combinations, 151
Kynurenic acid, for GBS meningitis, neuroprotective effect, neonatal rat model, 166

Lamivudine, for HIV-1 infection, in multidrug combinations, 355
Latent membrane protein-1, EBV, sequence variation, 710
Leishmania chagasi
American visceral leishmaniasis, IL-12 role in, 1515
recombinant antigen, as predictor of visceral leishmaniasis, 758
Leishmania donovani, relapse models, mouse model, 1041
Leishmania major, chemotherapy for, effect of polarity to T cell response, mouse model, 979
Leishmaniasis
chemokine expression in, 699
cutaneous, chemokine role, 699

visceral, amphotericin B lipid complex for, 762
Leukocyte, CMV infection of, 503
Lipopolysaccharide
E. coli, toxicity, prevention by tyrosine kinase inhibitor, mouse model, 927
hyporesponsiveness of *M. avium*–infected macrophages, 1030
IL-8 release via sCD14, 661
N. gonorrhoeae, sialylation effect, 1422
Lipopolysaccharide-specific protein, BPI, on monocyte surface, 252
Liver
disease, and risk of *Vibrio* infection, 1176
transplant recipients, CMV viremia in, prognostic significance, 446
Lyme disease (*See Borrelia* infection)
Lymphocyte, CD4 and CD8, cytotoxicity for HSV-infected keratinocytes, 7

Macrophage
alveolar, from smokers, iron and HIV replication in, 1045, 1046
inflammatory protein
1α and 1β, in leishmaniasis, 699
2, for *Klebsiella* pneumonia, mouse model, 159
NO synthase production, in ruminants, 971
Major outer membrane protein, *C. trachomatis,* 609, 950
Malaria
case definition in, 275, 276
mefloquine prophylaxis, long-term, in Dutch marines, 1506
PCR-based liquid hybridization assay, for diagnosis, 1284
P. falciparum
clinical immunity, 765
cytoadherence and rosetting, inhibition by antimalarials, 691
Marrow transplant, fungal infection in, amphotericin B colloidal dispersion for, 1208
Measles, mumps, rubella, and varicella, vaccine, combined, safety and immunogenicity, 731
Measles virus
detection by IgM EIA, 1470
epidemiology, molecular, 32
vaccine, immune response, in infants, 1320
Mefloquine, prophylaxis, long-term, for malaria, in Dutch marines, 1506
Meningitis
bacterial, pediatric, IL-10 in CSF, 1498
C. immitis, serologic diagnosis, 499
C. neoformans, experimental, fluconazole and flucytosine for, 1216
GBS, kynurenic acid for, neuroprotective effect, neonatal rat model, 166
H. influenzae, nonencapsulated, 180
O. anthropi, in pericardial tissue transplant recipients, 656
S. pneumoniae, HU-211, nonpsychotropic cannabinoid for, 735
tuberculous, pathogenesis, 1194
Microangiopathy, thrombotic, pathogenesis, Shiga toxin effects on, 1164
Microglia, *M. bovis* interaction with, 1194
Minocycline/rifampin, catheter coating, efficacy, rabbit, 418
Monoclonal antibody, against *C. neoformans,* 1222
Monocyte chemoattractant protein-1, in leishmaniasis, 699
Mycobacterium avium complex infection
bacteremia, treatment, mouse model, 750
disseminated
blood and tissue burden, 942
in AIDS, TNF-α and 1,25 dihydroxyvitamin D, 259
sputum isolates, 263
treatment for, 677
Mycobacterium avium
infected macrophages, hyporesponsiveness to LPS, 1030
intracellular growth, IL-10 role in, 410
Mycobacterium bovis, interaction with microglia, 1194
Mycobacterium tuberculosis
detection by PCR and strand displacement amplification, 934
isoniazid resistance, 196
Mycoplasma pneumoniae
detection by PCR, 1445
respiratory infection, pediatric, 1445
Myeloperoxidase, role in macrophage candidicidal activity, 1202

Necrotizing fasciitis, *S. pyogenes,* mouse model, 1399
Neisseria gonorrhoeae
infection, urethral, pathogenesis, 636
infectivity, sialylation effect, 1422
Neisseria meningitidis
antibody response, in children and adolescents, 1009
inflammatory response to, 172
septic shock
complement activation, 647
inflammatory mediators and hemostatic parameters, 1148
Neutrophil, dysfunction, in influenza A, 279
Nevirapine, for HIV-1 infection, in multidrug combinations, 355
Nitric oxide synthase, production, in bovine and caprine macrophages, 971
Norwalk-like viruses, diagnosis, 787
Nosocomial infection, *O. anthropi* meningitis, in pericardial tissue transplant recipients, 656

Ochrobactrum anthropi, meningitis, in pericardial tissue transplant recipients, 656
Onchocerca volvulus, detection by PCR, 773
Onchocerciasis, diethylcarbamazine for, posttreatment eosinophilia, 1277
Oocyst, *C. parvum,* infection, excretion patterns, 232
Opsonin, effect on *C. neoformans* interaction with murine macrophage-like cell, 1222
Otitis media
H. influenzae, bacteremia in, 180
S. pneumoniae
antibody-secreting cells, in children, 136
polysaccharide-protein conjugate vaccines for, chinchilla model, 119

p24 antigen, in HIV-1 infection, pediatric, 68, 574
Papillomavirus
human
and HIV infection, cervical abnormalities in Malawi women, 714
persistence in cervix, 794
serology, markers of sexual behavior, 1394
rabbit, DNA vaccine for, 314
Parainfluenza virus type 3, bronchiolitis and pneumonia, treatment for, cotton rat model, 598
Pelvic inflammatory disease, *C. trachomatis,* among sex workers in Nairobi, Kenya, 1437
Penicillium marneffei, infection, disseminated, in AIDS, seasonal variation, in Thailand, 1490
Phagocytosis, and intracellular killing of *Candida,* 1202
Pharyngitis, *S. pyogenes,* genetic markers, 896
Plasminogen, staphylokinase, *S. aureus,* 104
Plasmodium falciparum malaria
big endothelin in, 1281
case definition in, 275, 276
clinical immunity, 765
cytoadherence and rosetting, artemisinin derivatives, 691
Plasmodium infection, PCR-based liquid hybridization assay, for diagnosis, 1284
Pneumococcal conjugate vaccine, priming, antibody response, 256

Pneumocystis carinii infection
pneumonia, in transgenic B cell–deficient mice, 1034
nitric oxide and host defense, mouse model, 432
Pneumonia
CMV, diagnosis, 1297
hantavirus, community-acquired, in Baltimore, 237
K. pneumoniae, macrophage inflammatory protein for, mouse model, 159
M. pneumoniae, pediatric, PCR detection, 1445
parainfluenza type 3, treatment, cotton rat model, 598
P. carinii, in transgenic B cell–deficient mouse, 1034
S. pneumoniae, immunotherapy for, 1123
Poliovirus, vaccine, oral, and rotavirus vaccine, concurrent, 306
Polyethylene glycol–modified IL-2, for HIV infection, 1005
Polymerase chain reaction to detect
CMV, 523, 1072, 1481
cytokine mRNA, in syphilis lesions, 491
E. coli papG variants, 920
HBV and HCV, in syringes, 997
HIV-1, in infants, 68
human granulocytic ehrlichiosis, 1027
M. pneumoniae, 1445
M. tuberculosis, 934
O. volvulus, 773
S. intestinalis latent infection, in HIV infection, 1038
W. bancrofti, 1510
Polymerase chain reaction–based sequence-specific oligonucleotide hybridization analysis, in pulmonary tuberculosis, 669
Polyradiculopathy, ganciclovir-resistant CMV, 1481
Polysaccharide, capsular, *S. pneumoniae,* 113, 1347
Pregnancy, risk factor for tuberculosis, in HIV infection, 488
Presidential address, IDSA annual meeting, 517
Protease, *S. mansoni* larvae, infectivity, 1460
Pseudomonas aeruginosa
cystic fibrosis, antibody in, 513, 514
sepsis, neutropenic rat model, immunotherapy for, 1415
Pulsed-field gel electrophoresis, for *E. coli* O157:H7 outbreak analysis, 480
Puumala virus, HFRS, cytokine levels in, 38
Pyrimethamine, prophylaxis, for *Toxoplasma* encephalitis, in HIV infection, 91
Pyrimethamine-sulfadiazine for, *Toxoplasma* encephalitis, folic acid supplements to, 1294

Q fever, acute, infection route, mouse model, 484

Random amplification of polymorphic DNA, in immunosuppressed patients, 754
Respiratory syncytial virus, vaccine, attenuated, immunogenicity in rodents and nonhuman primates, 829
Retinitis, CMV, liposome-encapsulated cidofovir for, rabbit model, 18
Rifampin, for MAC infection, 677
Ritonavir, for HIV infection, immune response, 321
Rotavirus, vaccine, and oral poliovirus vaccine, concurrent, 306

Saquinavir for HIV-1 infection
HIV resistance to, in vivo, 1379
in multidrug combinations, 355
Schistosoma haematobium, infection, in adults and children, IgG4 and IgE responses after chemotherapy, 1242
Schistosoma mansoni infection
antibody response pattern, in Senegal, 1232
larval protease role, 1460
tetanus toxoid response impairment, in humans, 269
Sepsis
E. coli, hematoregulatory peptide SK&F 107647 for, 203
pneumococcal, recombinant PspA, 380
S. aureus, hematoregulatory peptide SK&F 107647 for, 203
Septata intestinalis, infection, latent, in HIV infection, 1038
Septic shock
E. coli LPS–induced, prevention by tyrosine kinase inhibitor, mouse model, 927
N. meningitidis, 647, 1148
P. aeruginosa, experimental, combination immunotherapy for, neutropenic rat model, 1415
S. epidermidis, induction of TNF-α release, 212
soluble CD14 function, 661
Shiga toxin, effects on endothelial cells, 1164
Simian immunodeficiency virus, vaccine, administration to mothers, effect on neonates, 1327
Sin Nombre hantavirus, epidemiology, 781
Small colony variants, *S. aureus,* induced by endothelial cells, 739
Small round-structured virus, gastroenteritis, outbreak, molecular investigation, 787
Smoking, as risk factor for HIV infection, in women, 1520, 1521
Staphylococcus, enterotoxin, food poisoning, 1263
Staphylococcus aureus
bacteremia, nosocomial, APACHE II use in, 914
furunculosis, recurrent, vitamin C for, 1502
sepsis, hematoregulatory peptide SK&F 107647 for, 203
small colony variants, induced by endothelial cells, 739
staphylokinase, plasminogen, 104
TSST-1, production, effect of tampon composition, 98, 1289, 1290
Staphylococcus epidermidis, peptidoglycan, induction of TNF-α release, 212
Staphylokinase, *S. aureus,* plasminogen, 104
Stavudine, for HIV-1 infection, 355, 1252
Strand displacement amplification, to detect *M. tuberculosis,* 934
Streptococcal toxic shock syndrome, Vβ repertoire in, 274
Streptococcus agalactiae, serotype V, emergence of, 365
Streptococcus pneumoniae
infection
in HIV infection, 857, 870
invasive, subtyping, 128
meningitis, nonpsychotropic cannabinoid for, 735
otitis media, 119, 136
pneumonia, immunotherapy for, 1123
resistant, spread in hospitalized children, 374
polysaccharide
capsular, antibody to, measurement by Farr assay vs. ELISA, 113
vaccine, 380, 387, 777, 778, 1014, 1347
Streptococcus pyogenes
IgG-binding proteins, 888
infection, invasive, genetic and phenotypic diversity, 901
isolates, genomic heterogeneity, 896, 901
necrotizing fasciitis, mouse model, 1399
toxic shock syndrome, Vβ repertoire in, 274
toxin production, in sepsis, 1399
Superoxide, *E. faecalis,* extracellular, production, 743
Surgical site infection, after hospital discharge, 963
Syncytium-inducing phenotype, HIV, changes in, after ddI, 1092
Syphilis, cytokine response in, 491

T cell
function, IL effect in HIV-infected persons, 1085
response, to CMV glycoprotein H, 1051
subsets, in HIV infection, and virus load, 468
Tetanus toxoid response impairment, in human *S. mansoni* infection, 269

Toxic shock syndrome, *S. pyogenes,* 901
Toxic shock syndrome toxin-1, production, tampons composition, 98, 1289, 1290
Toxoplasma encephalitis
in AIDS
genetic regulation of susceptibility, 265
pyrimethamine prophylaxis, 91
folic acid supplements to pyrimethamine-sulfadiazine for, 1294
Treponema pallidum, infection, cytokine response, 491
Tuberculosis
lymphocytes, alveolar, 1267
pulmonary, disease severity, HLA association for, 669
Tumor necrosis factor-α
for *B. burgdorferi* infection, 187
in disseminated MAC infection, in AIDS, 259
in GAS bacteremia, 619
in HFRS, 38
in multinucleated giant cells, 1194
release, induction by *S. epidermidis* peptidoglycan, 212
soluble receptor
in CSF, of children, in bacterial meningitis, 1498
in HIV infection, 464
Typhoid fever, *phoP/phoQ*-deleted *S. typhi* as vaccine, human trial, 1408
Tyrphostins, protective effect, against LPS toxicity, in *E. coli*–infected mice, 927

Upper respiratory infection, cytokine measurements in, markers of dilution, 1049, 1050
Urethral infection, *N. gonorrhoeae,* electron microscopic analysis of, 636
Urinary tract infection
E. coli, papG variants, 920
mouse model, inoculation conditions, 746

Vβ repertoire, in streptococcal toxic shock syndrome, 274
Vaccine
DNA, against rabbit papillomavirus, 314
E. coli J5 LPS, vaccine, 1157
HAV, attenuated, simian strain protects chimpanzees, 592
HCV, peptide, for HCV-specific CTL induction, 24
HIV-1, 52, 330, 340, 512, 1336
HSV-2 genital infection, animal model, 800
influenza, 44, 285, 453, 1313, 1467
Lyme disease, *B. burgdorferi* flagella-less mutant, mouse model, 1184
measles, mumps, rubella, and varicella, combined, 731
measles virus, immune response, in infants, 1320
poliovirus, oral, and rotavirus vaccine, concurrent, 306
rotavirus, and oral poliovirus vaccine, concurrent, 306
RSV, attenuated, immunogenicity in rodents and nonhuman primates, 829
SIV, administration to mothers, effect on neonates, 1327
S. pneumoniae, 83, 119, 256, 380, 387, 1014, 1347
typhoid fever, human trial, 1408
viral, nucleic acid, against HSV-2, 536
zoster, effect of boosting, in leukemic children, 450
Vaginitis, *C. glabrata,* mouse model, 425
Vancomycin
iv vs. oral, resistance development in enterococci, 1292, 1293
and teicoplanin, effect on resistance of fecal flora, 1129
Varicella-zoster virus, vaccine, effect of boosting, in leukemic children, 450
Vesicourethral reflux, avoidance, in UTI, mouse model, 746
Vibrio species, infections, in Florida, 1981–1993, 1176
Virulence
H. influenzae, nonencapsulated, 180
H. pylori, 1171
Visceral leishmaniasis, relapse models, 1041
Vitamin A, deficiency, in HIV infection, 507, 509
Vitamin C, for furunculosis, in patients with impaired neutrophil function, 1502

Wucheria bancrofti, infection
cytokines in, 1453
IL-10 production in, 769
PCR detection, 1510

Zalcitabine, and zidovudine or ddI combination therapy vs. zidovudine monotherapy for HIV infection, 1354
Zidovudine for HIV infection
effect on virus load, 849
in multidrug combinations, 355
pediatric, low-dose, ACTG 128, 1097
and zalcitabine or ddI combination therapy vs. zidovudine monotherapy, 1354